ESTRO 2025 - Abstract Book

S1600

Clinical – Mixed sites & palliation

ESTRO 2025

Conclusion: Hypo PT represents a feasible and safe approach for tumors located in different body sites. However, these preliminary results need to be confirmed with a larger cohort of patients with a longer follow up.

Keywords: proton therapy, re-RT

4431

Digital Poster Efficacy and safety of SBRT for intra-cardiac tumors and metastases: A systematic review and treatment outcome analysis Maiwand Ahmadsei* 1 , Lucas Mose* 2 , Sven Richter 3 , Fabio Dennstädt 2 , Sebastian M. Christ 1 , Nicolaus Andratschke 1 , Hossein Hemmatazad 2 , Daniel M. Aebersold 2 , Matthias Guckenberger 1 , Michael C. Mayinger* 1 , Mohamed Shelan* 2 1 Department of Radiation Oncology, University Hospital and University Zurich, Zurich, Switzerland. 2 Department of Radiation Oncology, University Hospital and University Bern, Bern, Switzerland. 3 Department of Hematology and Oncology, University Medical Center Augsburg, Augsburg, Germany Purpose/Objective: Primary cardiac tumors are rare, with an incidence of 0.0017% – 0.33%. Cardiac metastases are up to 100 times more common, particularly in melanoma. 1 Advances in cardiac imaging have increased detection rates of cardiac involvement. Improved systemic therapies have extended survival, leading to a rise in rare metastatic sites, including the heart. Yet, uniform treatment guidelines for radiation are lacking due to disease rarity. Historically, surgical excision was the main definitive treatment, with radiation therapy used for palliation. Advances in stereotactic body radiation therapy (SBRT) now allow precise, high-dose radiation delivery to cardiac metastases. MR-guided radiation therapy (MRgRT) enhances accuracy with real-time imaging and motion tracking. 2 This study aimed to systematically review the feasibility, doses, outcomes, and toxicity of SBRT for intra-cardiac tumors and metastases. Material/Methods: A systematic search of EMBASE and PubMed was conducted in May 2024 to identify studies on SBRT for intra cardiac targets. From 1,118 results, 18 studies met the inclusion criteria ( Figure 1 ). Patient and oncological